These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31612913)

  • 21. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL).
    Liu B; Li B; Zhou P; Yue W; Wang T; Wang J; Hu X; Zhang W; Chen J; Chen L; Gao L; He M; Yang J
    Clin Chim Acta; 2018 Jul; 482():191-198. PubMed ID: 29649456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China.
    Li T; Liu ZG; Liang PQ; Wang HT
    Leuk Lymphoma; 2017 Jul; 58(7):1624-1629. PubMed ID: 27868453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography.
    Liu T; Chen L; Pan J; Pan L; Hu J; Ji Z
    Acta Haematol; 2018; 139(3):148-157. PubMed ID: 29550822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FilGAP, a Rac-specific Rho GTPase-activating protein, is a novel prognostic factor for follicular lymphoma.
    Nishi T; Takahashi H; Hashimura M; Yoshida T; Ohta Y; Saegusa M
    Cancer Med; 2015 Jun; 4(6):808-18. PubMed ID: 25641953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
    Dalia S; Chavez J; Little B; Bello C; Fisher K; Lee JH; Chervenick P; Sokol L; Sotomayor E; Shah B
    Ann Hematol; 2014 Aug; 93(8):1305-12. PubMed ID: 24590536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.
    Li YJ; Yi PY; Li JW; Liu XL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Yao Y; Fan Z; Tang T; Jiang WQ
    Oncotarget; 2017 Jan; 8(3):4245-4256. PubMed ID: 28002803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma.
    Cao Y; Liu Z; Wu W; Qian Y; Shi Q; Shen R; Ouyang B; Xu P; Cheng S; Ye J; Lu Y; Wang C; Yang C; Wang L; Zhao W
    Front Med; 2019 Feb; 13(1):94-103. PubMed ID: 30706260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Survival of patients with diffuse large B-cell lymphoma].
    Salas-Delgado A; Hernández-Pliego MA
    Rev Med Inst Mex Seguro Soc; 2014; 52(3):276-81. PubMed ID: 24878086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.
    Howlader N; Morton LM; Feuer EJ; Besson C; Engels EA
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):174-9. PubMed ID: 26472423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
    Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
    Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
    Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
    Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma.
    Bo J; Zhao Y; Zhang S; Hua W; Wang S; Gao C; Wang Q; Li H; Yu L
    J Cancer Res Ther; 2016; 12(3):1189-1197. PubMed ID: 28054534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.